Biologics’ Big Bang: Novel BLAs Balance Breakthroughs And ‘Biobetters’
This article was originally published in Pharmaceutical Approvals Monthly
Both FDA’s biologics and drug centers posted historic BLA approval counts in 2014, combining to clear 21 novel biologics. The class is split between medical breakthroughs and “biobetters” offering incremental improvements, illustrating the maturation of the biotech industry.
You may also be interested in...
Twelve novel biologics in 2015 sets record, with 'biobetter' coagulation factors again making up largest group of new products.
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.
FDA hit high notes with new drug and therapeutic biologic approvals in 2014, turning in an 18-year high total of 41 novel agents – more than 20% with “breakthrough” therapy status – but the agency’s continuing consistency in review performance is the underlying theme.